EQRx Gives up on In-licensing Drugs from China for Lower Cost Therapies in the West
publication date: May 9, 2023
EQRx, a Cambridge, MA company, will change its business plan; the company will no longer in-license China-developed drugs for western markets, hoping to sell them at up to a 50% discount from the competition. EQRx will return rights to CStone Pharma for sugemalimab (a PD-L1 candidate) and nofazinlimab (a PD-1 antibody), and it will also give back rights to a JAK1 inhibitor from Lynk Pharmaceuticals. The company’s business plan may have become infeasible when the US FDA refused to approve a China-developed PD-1 drug based only on China trial data. Lilly acquired the candidate from Suzhou Innovent. More details....
Stock Symbol: (NSDQ: EQRX)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.